TY - JOUR T1 - Remdesivir as a tool to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact JF - medRxiv DO - 10.1101/2021.02.24.21252355 SP - 2021.02.24.21252355 AU - Guillaume Béraud AU - Jean-François Timsit AU - Henri Leleu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/01/2021.02.24.21252355.abstract N2 - Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. Strategies involving treating with remdesivir only patients with low-flow oxygen and patients with low-flow and high-flow oxygen were examined. Treating all eligible low-flow oxygen patients during the entirety of the second wave would have decreased hospital-bed occupancy in conventional wards by 4% [2%; 7%] and intensive care unit (ICU)-bed occupancy by 9% [6%; 13%]. Extending remdesivir use to high-flow-oxygen patients would have amplified reductions in ICU-bed occupancy by up to 14% [18%; 11%]. A minimum remdesivir uptake of 20% was required to observe decreases in bed occupancy. Dexamethasone had effects of similar amplitude. Depending on the treatment strategy, using remdesivir would, in most cases, generate savings (up to 722€) or at least be cost neutral (an extra cost of 34€). Treating eligible patients could significantly limit the saturation of hospital capacities, particularly in ICUs. The generated savings would exceed the costs of medications.Competing Interest Statement- GB participated to advisory boards for Gilead. GB gave lectures in symposia for Gilead, Pfizer and MSD. GB received research funding from Pfizer and BMS. - JFT reports participation to advisory board for Merck and Gilead related to covid-19 antiviral therapies. JFT reports outside of the submitted work research grants to his research group from Astellas, Thermofisher, Pfizer; Advisory board participation for Pfizer, Merck, Shionoghi, Medimune, Bayer, Nabriva and lectures in symposia for Biomerieux, Merck, Pfizer. - HL is employed by PHE which received funding from Gilead.Funding StatementHenri Leleu is employed by PH-Expertise which received funding from Gilead.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was necessary as we used open data publicly available, and anonymousAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study are publicly and freely available, and are mentioned as it. https://github.com/henrileleu/covid19 ER -